Andere talen Ironwood Pharmaceuticals, Inc.

Aandelen

IRWD

US46333X1081

Geschatte realtime Cboe BZX Andere beurzen 16:45:28 20-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
6,435 ^USD	-0,69%		-4,56%	-44,19%

09/05	Sectorupdate: Gezondheidszorgaandelen hoger aan het eind van de middag	MT
09/05	Sectorupdate: Aandelen in de gezondheidszorg stijgen in de middaghandel van donderdag	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Sector Update: Health Care Stocks Higher Late Afternoon	09/05
Sector Update: Health Care Stocks Gain in Thursday Afternoon Trading	09/05
Sector Update: Health Care	09/05
Ironwood Pharmaceuticals' Shares Fall After Q1 Swings to a Non-GAAP Loss, Revenue Declines; 2024 Revenue Guidance Cut	09/05
Ironwood Pharmaceuticals : 1Q 2024 Investor Update	09/05
(IRWD) IRONWOOD PHARMACEUTICALS Expects Fiscal Year 2024 Revenue Range $405M - $425M	09/05
Earnings Flash (IRWD) IRONWOOD PHARMACEUTICALS Reports Q1 Revenue $74.9M	09/05
Ironwood: Q1 Earnings Snapshot	09/05
Ironwood Pharmaceuticals, Inc. Revised Earnings Guidance for Its Fiscal Year 2024	09/05
Ironwood Pharmaceuticals Reports First Quarter 2024 Results	09/05
Ironwood Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
Ironwood Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference	06/05
Ironwood Pharmaceuticals to Present New Data on Once-Weekly Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) at Digestive Disease Week® 2024	01/05
Ironwood Pharmaceuticals to Host First Quarter 2024 Investor Update Call	25/04
Ironwood Pharmaceuticals : ESG/Responsibility	25/04
La biotech helvétique a profité d'un regain de fonds en 2023	23/04
Ironwood Pharmaceuticals Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD)	28/03
Ironwood Pharmaceuticals, Inc. Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD)	28/03
Ironwood Pharmaceuticals Announces Positive Topline Results from Global Phase III Trial of Once-Weekly Apraglutide in Adults with Short Bowel Syndrome with Intestinal Failure	01/03
Wall Street Set to Open Higher Thursday as Inflation Data Meets Forecasts	29/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Ironwood Pharmaceuticals, Inc.

Aandelen

IRWD

US46333X1081

Andere talen

Filters